300 related articles for article (PubMed ID: 26905369)
1. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
[TBL] [Abstract][Full Text] [Related]
2. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
3. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
4. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
5. A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection.
Uchida H; Chan J; Goins WF; Grandi P; Kumagai I; Cohen JB; Glorioso JC
J Virol; 2010 Dec; 84(23):12200-9. PubMed ID: 20861246
[TBL] [Abstract][Full Text] [Related]
6. B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies.
Patrusheva I; Perelygina L; Torshin I; LeCher J; Hilliard J
J Virol; 2016 Oct; 90(20):9420-32. PubMed ID: 27512063
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255
[TBL] [Abstract][Full Text] [Related]
8. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity.
Yu Z; Adusumilli PS; Eisenberg DP; Darr E; Ghossein RA; Li S; Liu S; Singh B; Shah JP; Fong Y; Wong RJ
Mol Ther; 2007 Jan; 15(1):103-13. PubMed ID: 17164781
[TBL] [Abstract][Full Text] [Related]
9. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.
Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
PLoS Pathog; 2017 Apr; 13(4):e1006352. PubMed ID: 28423057
[TBL] [Abstract][Full Text] [Related]
10. Nectin-2-mediated entry of a syncytial strain of herpes simplex virus via pH-independent fusion with the plasma membrane of Chinese hamster ovary cells.
Delboy MG; Patterson JL; Hollander AM; Nicola AV
Virol J; 2006 Dec; 3():105. PubMed ID: 17192179
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC(nectin-1) with different affinities.
Connolly SA; Whitbeck JJ; Rux AH; Krummenacher C; van Drunen Littel-van den Hurk S; Cohen GH; Eisenberg RJ
Virology; 2001 Feb; 280(1):7-18. PubMed ID: 11162814
[TBL] [Abstract][Full Text] [Related]
12. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
13. Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism.
Manoj S; Jogger CR; Myscofski D; Yoon M; Spear PG
Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12414-21. PubMed ID: 15273289
[TBL] [Abstract][Full Text] [Related]
14. Structure-function analysis of herpes simplex virus glycoprotein B with fusion-from-without activity.
Roller DG; Dollery SJ; Doyle JL; Nicola AV
Virology; 2008 Dec; 382(2):207-16. PubMed ID: 18950828
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
16. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus.
Krummenacher C; Baribaud F; Ponce de Leon M; Baribaud I; Whitbeck JC; Xu R; Cohen GH; Eisenberg RJ
Virology; 2004 May; 322(2):286-99. PubMed ID: 15110526
[TBL] [Abstract][Full Text] [Related]
17. Mapping sites of herpes simplex virus type 1 glycoprotein D that permit insertions and impact gD and gB receptors usage.
Fan Q; Kopp S; Connolly SA; Muller WJ; Longnecker R
Sci Rep; 2017 Mar; 7():43712. PubMed ID: 28255168
[TBL] [Abstract][Full Text] [Related]
18. Use of chimeric nectin-1(HveC)-related receptors to demonstrate that ability to bind alphaherpesvirus gD is not necessarily sufficient for viral entry.
Geraghty RJ; Fridberg A; Krummenacher C; Cohen GH; Eisenberg RJ; Spear PG
Virology; 2001 Jul; 285(2):366-75. PubMed ID: 11437670
[TBL] [Abstract][Full Text] [Related]
19. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
20. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy.
Huang YY; Yu Z; Lin SF; Li S; Fong Y; Wong RJ
J Clin Endocrinol Metab; 2007 May; 92(5):1965-70. PubMed ID: 17327376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
